Charles Schwab’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$7.2B Buy
6,001,955
+104,505
+2% +$107M 0.96% 14
2026
Q1
$5.42B Buy
5,897,450
+139,244
+2% +$141M 0.83% 25
2025
Q4
$6.19B Buy
5,758,206
+125,815
+2% +$120M 0.96% 12
2025
Q3
$4.3B Buy
5,632,391
+272,738
+5% +$203M 0.69% 26
2025
Q2
$4.18B Buy
5,359,653
+112,105
+2% +$87.1M 0.72% 26
2025
Q1
$4.33B Buy
5,247,548
+212,464
+4% +$177M 0.81% 25
2024
Q4
$3.89B Buy
5,035,084
+199,864
+4% +$165M 0.72% 25
2024
Q3
$4.28B Buy
4,835,220
+10,204
+0.2% +$9.17M 0.82% 22
2024
Q2
$4.37B Buy
4,825,016
+150,756
+3% +$121M 0.83% 17
2024
Q1
$3.64B Buy
4,674,260
+113,707
+2% +$80.9M 0.84% 17
2023
Q4
$2.66B Buy
4,560,553
+125,242
+3% +$73.1M 0.68% 27
2023
Q3
$2.38B Buy
4,435,311
+88,016
+2% +$45.4M 0.68% 27
2023
Q2
$2.04B Buy
4,347,295
+33,311
+0.8% +$14M 0.58% 32
2023
Q1
$1.48B Buy
4,313,984
+31,847
+0.7% +$10.7M 0.45% 37
2022
Q4
$1.57B Buy
4,282,137
+74,736
+2% +$26.5M 0.5% 35
2022
Q3
$1.36B Buy
4,207,401
+370,521
+10% +$117M 0.49% 34
2022
Q2
$1.24B Sell
3,836,880
-32,394
-0.8% -$9.72M 0.43% 40
2022
Q1
$1.11B Buy
3,869,274
+83,299
+2% +$21.4M 0.33% 56
2021
Q4
$1.05B Buy
3,785,975
+67,876
+2% +$17.2M 0.31% 64
2021
Q3
$859M Buy
3,718,099
+52,452
+1% +$12.9M 0.28% 68
2021
Q2
$841M Buy
3,665,647
+79,606
+2% +$16M 0.28% 67
2021
Q1
$670M Sell
3,586,041
-3,041
-0.1% -$595K 0.25% 75
2020
Q4
$606M Buy
3,589,082
+9,802
+0.3% +$1.46M 0.24% 81
2020
Q3
$530M Sell
3,579,280
-309,768
-8% -$47.9M 0.24% 84
2020
Q2
$639M Buy
3,889,048
+89,685
+2% +$13.8M 0.31% 59
2020
Q1
$527M Sell
3,799,363
-69,027
-2% -$9.48M 0.31% 65
2019
Q4
$508M Sell
3,868,390
-46,369
-1% -$5.37M 0.27% 68
2019
Q3
$438M Sell
3,914,759
-66,340
-2% -$7.39M 0.26% 72
2019
Q2
$441M Sell
3,981,099
-95,911
-2% -$11.3M 0.27% 68
2019
Q1
$529M Buy
4,077,010
+17,875
+0.4% +$2.17M 0.34% 52
2018
Q4
$470M Sell
4,059,135
-5,963
-0.1% -$666K 0.36% 47
2018
Q3
$436M Sell
4,065,098
-122,303
-3% -$12.2M 0.29% 60
2018
Q2
$357M Sell
4,187,401
-147,639
-3% -$12.1M 0.26% 66
2018
Q1
$335M Buy
4,335,040
+85,455
+2% +$6.88M 0.26% 66
2017
Q4
$359M Buy
4,249,585
+135,951
+3% +$11.6M 0.28% 57
2017
Q3
$352M Buy
4,113,634
+553,349
+16% +$45.4M 0.31% 53
2017
Q2
$293M Buy
3,560,285
+386,091
+12% +$31.5M 0.28% 57
2017
Q1
$267M Buy
3,174,194
+228,673
+8% +$18.3M 0.27% 59
2016
Q4
$217M Buy
2,945,521
+48,134
+2% +$3.58M 0.24% 72
2016
Q3
$233M Buy
2,897,387
+19,660
+0.7% +$1.57M 0.27% 61
2016
Q2
$227M Sell
2,877,727
-18,969
-0.7% -$1.43M 0.28% 59
2016
Q1
$209M Sell
2,896,696
-690,206
-19% -$52.2M 0.27% 63
2015
Q4
$302M Buy
3,586,902
+129,362
+4% +$10.7M 0.41% 44
2015
Q3
$289M Buy
3,457,540
+316,393
+10% +$26.7M 0.43% 40
2015
Q2
$262M Buy
3,141,147
+2,261
+0.1% +$172K 0.36% 53
2015
Q1
$228M Buy
3,138,886
+139,074
+5% +$9.9M 0.32% 57
2014
Q4
$207M Sell
2,999,812
-150,112
-5% -$10.1M 0.31% 54
2014
Q3
$204M Buy
3,149,924
+93,158
+3% +$5.9M 0.34% 53
2014
Q2
$190M Buy
3,056,766
+39,684
+1% +$2.37M 0.32% 59
2014
Q1
$178M Sell
3,017,082
-204,464
-6% -$11.4M 0.32% 58
2013
Q4
$164M Buy
3,221,546
+50,100
+2% +$2.51M 0.31% 61
2013
Q3
$161M Buy
3,171,446
+108,142
+4% +$5.66M 0.33% 54
2013
Q2
$154M Buy
+3,063,304
New +$167M 0.34% 55

Other funds holding LLY

Charles Schwab's LLY Position: Q2 2026 in Review

Charles Schwab increased its Eli Lilly (LLY) stake by 1.8% in Q2 2026, buying an estimated $107M and bringing the position to 6,001,955 shares worth $7.2B. The position accounts for 0.96% of the portfolio, ranked #14.

Charles Schwab first reported a position in LLY in Q2 2013 and has held it in 53 quarters since. 4,593 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Charles Schwab held 6,001,955 shares of Eli Lilly worth $7.2B as of Q2 2026.
  • Charles Schwab bought 104,505 Eli Lilly shares in Q2 2026, an estimated $107M.
  • Eli Lilly made up 0.96% of Charles Schwab's portfolio in Q2 2026, its #14 holding.
  • Charles Schwab first reported a position in Eli Lilly in Q2 2013 and has held it in 53 quarters since.
  • 4,593 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.